Interim Results for the Six Months’ to 30 June 2005
Post navigation
←
ReGen Therapeutics announces grant of U.S. patent on use of Colostrinin(tm) to promote induction of Cytokines
ReGen Therapeutics Plc places £1,556,000 of shares
→
Home
About Us
Our History
Directors
Products & Research
Colostrinin as a nutraceutical
Pharmaceuticals – Peptides
Pharmaceuticals – Zolpidem
Presentations
News
Announcements
Events Calendar
Email News Alerts
Contact Us
